Cell and Gene Therapy Manufacturing Services Market Trends, Share, Scope, Size and Growth 2030

The cell and gene therapy manufacturing services market size is projected to reach US$ 26,724.90 million by 2030 from US$ 7,581.97 million in 2022. The market is expected to register a CAGR of 17.1% during 2022–2030. Automation of manufacturing services for cell and gene therapy is likely to remain a key trend in the market.

Cell and Gene Therapy Manufacturing Services Market Analysis

In recent years, the outsourced cell and gene manufacturing sector has undergone significant expansion and change. As cell and gene therapies progress, drug innovator firms are progressively depending on service providers to fulfill their manufacturing requirements. Outsourcing enables innovators to take advantage of the specialized expertise and capabilities of contract development and manufacturing organizations (CDMOs) to reduce costs and expedite time to market. The landscape of cell and gene therapy manufacturing has evolved over the past five years, with a shift towards more sophisticated platforms allowing scale-up, increased automation, and enhanced quality systems, shaping the contract manufacturing industry. With the growing number of approved cell and gene therapy products in the market each year, the need to enhance processes is becoming increasingly important.

Cell and Gene Therapy Manufacturing Services Market Overview

Both publicly and privately funded contract biopharmaceutical manufacturing has increased as a result of the surge in new biopharmaceutical products competing for approval. As a result, while established industry players are attempting to hold onto their positions and lead, new organizations are engaged in providing manufacturing services for cell and gene therapy. Healthcare policies in many regions now prioritize the ability to manufacture pharmaceutical (small molecule) products of all kinds. Additionally, a shift toward larger-molecule biomanufacturing, recombinant therapies, and increasingly complex biologics has occurred in many regions.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Cell and Gene Therapy Manufacturing Services Market: Strategic Insights

Cell and Gene Therapy Manufacturing Services Market

• 
  CAGR (2022 - 2030)

  17.1%
• Market Size 2022
  US$ 7,581.97 Million
• Market Size 2030
  US$ 26,724.90 Million

Market Dynamics

GROWTH DRIVERS

• Increase In the outsourcing of Cell and Gene Therapy Manufacturing

FUTURE TRENDS

• Tech transfer to expand the capabilities by biopharmaceutical players

OPPORTUNITIES

• The Emergence of resourceful Service Providers

Key Players

• Thermo Fisher Scientific Inc
• Merck KGaA
• Charles River Laboratories International Inc
• Lonza Group AG
• WuXi AppTec Co Ltd
• Catalent Inc
• Takara Bio Inc
• Nikon Corp
• FUJIFILM Holdings Corp
• National Resilience Inc

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Cell Therapy
• Gene Therapy

Indication

• Cancer
• Orthopaedics

Application

• Clinical Manufacturing
• Commercial Manufacturing

End User

• Pharmaceutical
• Biotechnology Companies
• Contract Research Organization

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Cell and Gene Therapy Manufacturing Services Market Drivers and Opportunities

Increase in Demand for Cell and Gene Therapy Manufacturing Favors Market Growth

Significant therapeutic advances in cell and gene therapy manufacturing services have resulted from the growing cell therapy research activities. The industry is striving to expand its manufacturing scale and overall accessibility to a broader population while emphasizing the advantages of advanced therapy medicinal products (ATMPs). The increasing complexity of personalized medicine necessitates the development of manufacturing capabilities to keep up with demand and guarantee patient access to these innovative treatments. Contract manufacturing now has more options due to the rise in global production. Funding for newly approved biopharmaceutical products, as well as contract biopharmaceutical manufacturing, has increased from both public and private sources. Worldwide organizations offer manufacturing services for cell and gene therapy, and well-established industry participants strive to sustain their operations.  Thus, the emerging focus on the development of cell therapy manufacturing is likely to drive the growth of the market.

Strategic Initiatives by Key Players

Because of the rise in approvals and investments, there is an increasing need to manufacture therapies at preclinical, clinical, and commercial stages. Key players are making strategic development investments, which are opening up a lot of market opportunities. As an illustration of the rising need for cell and gene therapy manufacturing services, Bristol Myers Squibb and the start-up Cellares inked a $380 million deal in May 2024. In August 2023, Cellares completed a $255 million series C funding round, with BMS among the investors. Cellares will make chimeric antigen receptor (CAR) T-cell treatments for BMS. BMS will reserve spaces in Cellares' automated cell therapy manufacturing machines, or Cell Shuttle machines, in accordance with the terms of the agreement. With the money from the BMS sale, Cellares intends to open more locations in the US, Europe, and Japan in addition to running the ones in San Francisco and New Jersey.

Cell and Gene Therapy Manufacturing Services Market Report Segmentation Analysis

Key segments that contributed to the derivation of the cell and gene therapy manufacturing services market analysis are type, indication, application, and end user.

• Based on type, the cell and gene therapy manufacturing services market is divided into cell therapy and gene therapy. Cell therapy is further sub-segmented into autologous and allogeneic therapy. Gene Therapy is further sub-segmented into viral and non-viral vectors.
• By indication, the market is categorized into cancer, orthopedics, and others. The cancer segment held the largest share of the market in 2022.
• By application, the market is categorized into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held the largest share of the market in 2022.
• By end user, the market is segmented into pharmaceutical and biotechnology companies and contract research organizations (CROs). The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022.

Cell and Gene Therapy Manufacturing Services Market Share Analysis by Geography

The geographic scope of the cell and gene therapy manufacturing services market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

The market for manufacturing services related to cell and gene therapy is anticipated to expand as a result of the rising demand for these products. This growth is linked to an increase in startups, an increase in R&D activities, and increased investments in the construction of cell and gene therapy manufacturing facilities in the US and Canada.

Additionally, for the forecast period, the Asia Pacific market has grown significantly at a robust CAGR. This growth can be attributed to a number of factors, including the growing need for advanced treatment solutions, favorable regulatory scenarios, and an increasing emphasis on research and development activities. Additionally, during the forecast period, the Asia Pacific market is expected to be driven by the expansion of healthcare infrastructure and rising investments meant to stimulate research activities.

Cell and Gene Therapy Manufacturing Services Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Cell and Gene Therapy Manufacturing Services Market News and Recent Developments

The cell and gene therapy manufacturing services market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the cell and gene therapy manufacturing services market are listed below:

• RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand. The integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market. (Source: RoslinCT, Press Release, June 2023)
•  Cincinnati Children's Hospital Medical Center and the research service provider CTI Clinical Trial & Consulting Services have agreed to form a company that will focus on providing cell and gene therapy manufacturing services to the biotechnology and pharmaceutical industries. (Source: Cincinnati Children's Hospital Medical Center, Press Release, December 2021)

Cell and Gene Therapy Manufacturing Services Market Report Coverage and Deliverables

The “Cell and Gene Therapy Manufacturing Services Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:

• Cell and gene therapy manufacturing services market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Cell and gene therapy manufacturing services market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Cell and gene therapy manufacturing services market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the cell and gene therapy manufacturing services market
• Detailed company profiles